ClinicalTrials.gg
CompletedNCT00528684Updated Oct 2, 2014

Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas

A Phase 1 interventional study of REOLYSIN® in Malignant Glioma, sponsored by Oncolytics Biotech. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-02.

Sponsored by Oncolytics Biotech · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 851 studies in Glioma with a site in United States — 142 open to participants now, 229 under way, 6 of them phase 3. Glioma · United States.

Enrollment
484th of 737
18 · median 30
Started
2006
with 21 others
Phase 1
338 of 851
63 open now
Registered
164th of 851
by date

Among the 851 studies in Glioma with a site in United States, this one is the 484th largest by enrollment of the 737 interventional ones that give a count, is one of 22 that started in 2006, is one of 338 in phase 1, and was the 164th registered.

Glioma

1,453 studies on the registry are indexed under Glioma; 349 are open to participants now.

Browse Glioma studies →

Open to participants now

142 of the 851 studies in Glioma with a site in United States are open now. Recruiting first, the newest first:

137 more — sign in →

All 142 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 267 Glioma studies recruiting now, 164 (61%) set no upper age limit and 57 (21%) stop at 75 or younger; 63 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 851 studies in Glioma with a site in United States, or all of them as a file.
02

Study summary

RATIONALE: Oncolytic viruses such as reovirus (REOLYSIN®) can specifically kill tumor cells while leaving healthy cells unharmed.

PURPOSE: This phase I/II study investigates the maximum tolerated dose (MTD), dose limiting toxicity (DLT) and anti-tumor effect of intralesional administration of REOLYSIN® therapeutic reovirus in patients with malignant glioma with evaluable disease which is progressive/recurrent despite surgery and/or radiotherapy with or without chemotherapy. (The phase I portion of the study is currently enrolling patients.)

Read the detailed description

Oncolytic viruses, such as reovirus, are those viruses which specifically destroy cancer cells. Reovirus is a common virus that does not cause disease, and has been shown to be associated with only minor flu-like symptoms. REOLYSIN® is a formulation of the live, replication-competent wild-type reovirus that selectively replicates in tumor cells, while leaving healthy cells unharmed.

This phase I/II multi-center study follows a standard design utilizing therapeutic viral dosage escalation. The phase I portion of the trial will evaluate the doses of intralesional REOLYSIN titrated to a maximum tolerated dose (MTD). The objective of the phase II portion of the study is to assess tumor response. The proportion of patients surviving to six months and the safety of REOLYSIN® are secondary objectives.

Each patient enrolled in the study will receive a single infusion of REOLYSIN® over 72 hours. Patients will remain in hospital for at least 90 hours after initiation of infusion. Following REOLYSIN® administration, each patient will be followed for at least 12 weeks (Phase I) and at least 6 months (Phase II) with regular evaluation visits (weekly and then monthly). Evaluations will include tumor measurements, serial neurologic exams and functional performance status assessments at baseline, prior to hospital discharge, and at weeks 4, 8, 12, 16 and 24 after REOLYSIN® therapy. Changes in performance will be assessed using the Karnofsky Performance Status scale. Subjects will also undergo serial blood sampling for evaluation of viral RNA, hematology and biochemistry.

03

Conditions studied

  • Malignant Glioma

Keywords

  • Oncolytics Biotech
  • cancer alternative therapies
  • malignant glioma
  • glioblastoma multiforme
  • oncolytic virus
  • reovirus
  • REOLYSIN
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Abbreviated Inclusion Criteria:

  • PHASE I: 1st, 2nd or 3rd recurrence of: glioblastoma multiforme; gliosarcoma; anaplastic astrocytoma; anaplastic mixed glioma; or anaplastic oligodendroglioma
  • PHASE II: 1st recurrence of glioblastoma multiforme (only)
  • Progressing/recurrent lesion which is ≥1cmx1cm. For the Phase II study the lesion must be ≤5cmx5cm, defined by MRI only
  • Be fully recovered from any prior therapy
  • Have been treated at the time of original diagnosis by surgery and external beam radiation to a dose of at least 5000 cGy; radiotherapy completed at least 6 weeks before REOLYSIN® therapy
  • Any intracranial surgery, except for stereotactic needle , must have occurred at least 4 weeks before REOLYSIN® therapy
  • Any anti-cancer drug therapy must have been completed at least 4 weeks (6 weeks in the case of prior nitrosourea therapy) before REOLYSIN® therapy
  • Have a of ≥8 weeks and a Performance Status (KPS) of ≥60
  • Absolute neutrophils ≥1.5 x10\^9/L; ≥100g/L; ≥100 x 10\^9/L
  • ≥1.5 x ; total ≥1.5 x ULN
  • Serum creatinine ≤1.5 x ULN
  • with no evidence of active, acute cardiovascular disease
  • PT within normal limit
  • Women of must have a negative pregnancy test
  • Reside or have suitable living arrangements within a reasonable geographical area of the study site and be able to participate in all follow-up visits
  • Patients requiring must be on a stable dose of steroid for at least two weeks prior to baseline MRI and when entered in the study. Maximum daily dose of 24 mg/day of dexamethasone/decadron or equivalent

Abbreviated Exclusion Criteria:

  • Patients who are sexually active and not willing to use barrier methods of ; women who are breastfeeding
  • Patients with unstable or serious concurrent medical or psychiatric conditions that would interfere with study treatment or follow-up
  • Patients with more than one discrete enhancing lesion on MRI, or radiographic evidence of satellite lesions or not obviously contiguous by FLAIR imaging
  • Patients who may require further neurosurgery within 4 weeks after REOLYSIN® treatment
  • Patients with a prior history of encephalitis, multiple sclerosis or other significant chronic CNS disease
  • Patients who have evidence of a current CNS infection, meningeal gliomatosis or gliomatosis cerebri
  • Patients with tumor that to be treated would require needle or catheter passage through a ventricle, the posterior fossa or basal ganglia; or patients with tumors invading the ventricle
  • Patients who have previously participated in experimental viral therapy protocols
  • Patients who have had prior intratumoral gene therapy or other intratumoral therapies
  • Patients who have had Gliadel wafer therapy less than 6 months prior to enrollment
  • Patients who have a history of bleeding disorders including congenital or acquired coagulopathies
  • Patients who have a known history of hepatitis or tuberculosis
  • Patients who have a known history of hereditary or acquired immunodeficiency including infection
  • Patients who have impaired non-neurological organ function (>Grade 1)
  • Patients who have used systemic antiviral (or potentially antiviral) therapies within 28 days of enrollment
  • Patients who have had brachytherapy or radiosurgery to the brain at any time
  • Patients with previous or concurrent at other sites (except surgically-cured carcinoma in situ of the cervix and non-melanoma skin cancer)
  • Prior or current medical history indicating that a patient may be significantly
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Interventions

  • BiologicalREOLYSIN®

    REOLYSIN® is administered as a single intratumoral infusion over 72 hours. Dose levels in Phase 1 will be 1x10E8, 3x10E8, 1x10E9, 3x10E9, 1x10E10 TCID50. The dose level for Phase 2 will be the top dose reached in Phase 1.

06

What researchers measure

Primary outcomes

  1. determine the maximum tolerated dose

    Time frame: in the first 28 days following REOLYSIN® administration

  2. and response rate of treated tumors

    Time frame: evaluated monthly for 6 months following REOLYSIN® administration

  3. determine the dose limiting toxicity

    Time frame: in the first 28 days following REOLYSIN® administration

Secondary outcomes

  1. Determine the patient survival

    Time frame: patients are in follow up for up to six months

  2. functional status using the Karnofsky Performance Status scale and Clinical Neurological Assessment

    Time frame: evaluated monthly for up to 6 months

  3. time to progression for the treated tumor

    Time frame: evaluated monthly for up to 6 months

07

Study locations

3 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • The Ohio State University Medical Center and Arthur G. James Cancer Hospital and Richard J. Solove Research Center
    Columbus, Ohio 43210, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2006, a primary completion of Apr 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2007
First posted
Sep 12, 2007
Start
Jul 2006
Primary completionActual
Apr 2010
CompletionActual
Jun 2010
Last update
Oct 2, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00528684
Lead sponsor
Oncolytics Biotech
Responsible party
Sponsor
First posted
Sep 12, 2007
Start date
Jul 2006
Primary completion
Apr 2010
Completion
Jun 2010
Last update
Oct 2, 2014

Study contacts

James M Markert, MD
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pelareorep

Start the discussion